President Donald Trump has ordered a 100% tariff on certain imported patented medicines, part of a broader push to shift pharmaceutical production and pricing toward the United States. The new rate targets patented or branded drugs manufactured outside the U.S., while generic medicines are currently exempt from the measure.
The directive allows carve‑outs for companies that either already manufacture in the U.S. or commit to building or expanding American facilities. Firms that enter into pricing agreements with the administration can also qualify for reduced or zero tariffs under the policy. The move is framed as a way to pressure drugmakers to onshore production and reduce U.S. dependence on foreign‑made treatments.
Larger pharmaceutical companies are reportedly given about 120 days before the full tariff applies, while smaller firms get roughly 180 days to adjust. During this period, some companies may receive temporary rate reductions or phased‑in treatment if they announce plans to relocate manufacturing to the United States. The policy also includes separate treatment for imports from the European Union, Japan, South Korea, Switzerland, and the United Kingdom, which remain under existing trade arrangements and are not subject to the same 100% wall.
For India, the immediate impact appears limited, as Indian pharmaceutical exports to the U.S. are dominated by generic medicines, which are currently outside the scope of the new tariff. However, any future expansion of the measure to branded or specialty drugs could raise pressure on Indian manufacturers active in higher‑value segments. The administration has signaled that the policy may be adjusted as negotiations with drugmakers continue and as more companies commit to domestic production.
Read Article: Perplexity AI Sued Over Alleged User Data Sharing With Meta, Google
